Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health-related bodily pain among African American women ...

Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterized by persistent damage to multiple organs and tissues, including the skin, kidneys, cardiovascular system, and brain.

Zen M, Gatto M, Doria A. Defining the targets in SLE management: Insights and unmet gaps. Ann Rheum Dis. 2022;81(11):1483–85. doi: 10.1136/ard-2022-222991. Discuss the different treatment approach in ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids. 2 As ...

Understanding the factors contributing to poor treatment adherence, recognizing its consequences, and developing effective strategies to enhance adherence are key to improving patient outcomes in ...

Systemic lupus erythematosus (SLE) is associated with a wide variety of ocular manifestations. Some of these include uveitis, occlusive retinal vasculitis, (epi)scleritis and keratitis. Uveitis is an ...

Objective Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently ...

Background Kidney involvement is common in lupus. Lupus and kidney diseases incur poor outcomes in people from racial/ethnic minority groups. Previous studies have utilized the national registry of ...

Background Activation of Type I interferons (IFNs) and a wide array of innate and adaptive immune mediators are hallmarks of the pathogenesis of systemic lupus erythematosus (SLE) and activation of ...

In lupus, TLR7 and TLR9 mediate loss of tolerance to RNA and DNA, respectively. Yet, TLR7 promotes while TLR9 protects from disease, implying differences in signaling. To dissect this ‘TLR paradox’, ...